Following on from information provided to NICE by the company in February 2010, the appraisal of Temozolomide for the treatment of advanced and metastatic melanoma [ID316] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 316 |
| Referral date | 01 June 2008 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Assessment Group / Evidence Review Group: | TBC |
| Communications manager: | TBC |
| Executive Lead: | TBC |
| Project manager: | TBC |
| Technical Lead: | TBC |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 29 December 2022 | Discontinued. Following on from information provided to NICE by the company in February 2010, the appraisal of Temozolomide for the treatment of advanced and metastatic melanoma [ID316] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 19 February 2010 |
The manufacturer of temozolomide has advised us that regulatory approval for this technology is not being sought at the present time. The Institute has therefore decided to remove this appraisal from its current work programme. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. If you have any comments or concerns please do not hesitate to contact the Project Manager for this appraisal, Cathryn Hall (020 7045 2240 or email: cathryn.hall@nice.org.uk) |
For further information on our processes and methods, please see our CHTE processes and methods manual